August 2011 Vol 4, No 5
CHICAGO—The phase 3 ACT-1 trial suggests that amrubicin may have some advantages over topotecan as secondline treatment for small-cell lung cancer (SCLC). Read More ›
CHICAGO—Several studies addressed key questions in the treatment of non-Hodgkin lymphoma (NHL). One evaluated a shorter, more intense rituximab- based regimen, and another evaluated the benefit of autologous stem-cell transplantation (ASCT) in high-risk patients. Read More ›
By Dawn Lagrosa
For breast cancer patients aged 66 years and older, nurses should consider comorbidities when discussing prognosis, according to an analysis of Surveillance, Epidemiology and End Results–Medicare data.
Read More ›Page 2 of 2
- 1
- 2